Genómica, a company of the Zeltia Group (ZEL.MC) leader in molecular diagnostic products, is developing an updated version of its product Clart PneumoVir for the specific and urgent detection of the New A/H1N1 Influenza. For the development of this test, Genómica is collaborating with various Spanish and international hospitals. Over the past two months a great number of suspicious samples have been analyzed. Positive and negative cases were confirmed in all the tests and the results have been validated by the different Spanish and international centres of reference.

The new diagnostic test, called Clart PneumoVir/Flu A, is estimated to be available this autumn to coincide with the 2009/2010 flu campaign. The company currently sells the product Clart PneumoVir which allows a single panel to detect the 17 most common viruses causing human respiratory infections. It is possible that the innovative platform Clart, may also detect patient's H1N1 infection of porcine origin in a single analysis.

Clart technology allows the automatic processing of eight samples simultaneously. It also allows for a diagnosis in eight hours after the sample is delivered to the hospital. The doctor can then take a fast decision on the best treatment for each patient.

Genomica is the first Spanish company in Molecular Diagnostics highly experienced in the analysis of genetic identification.